Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Chemistry and pharmacology of imexon and related cyanoaziridines.

Remers WA, Dorr RT.

Curr Med Chem. 2012;19(33):5745-53.

PMID:
22998528
2.

Chemical basis for the biological activity of imexon and related cyanoaziridines.

Iyengar BS, Dorr RT, Remers WA.

J Med Chem. 2004 Jan 1;47(1):218-23.

PMID:
14695835
3.

Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.

Dorr RT, Wisner L, Samulitis BK, Landowski TH, Remers WA.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1039-49. doi: 10.1007/s00280-011-1784-8.

4.

Novel antitumor 2-cyanoaziridine-1-carboxamides.

Iyengar BS, Dorr RT, Alberts DS, Hersh EM, Salmon SE, Remers WA.

J Med Chem. 1999 Feb 11;42(3):510-4.

PMID:
9986721
5.

Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro.

Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE.

J Natl Cancer Inst. 1992 Aug 19;84(16):1238-44.

PMID:
1640482
6.

Phase I trial of imexon in patients with advanced malignancy.

Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R.

J Clin Oncol. 2007 May 1;25(13):1779-84.

PMID:
17470869
7.

Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.

Pourpak A, Meyers RO, Samulitis BK, Sherry Chow HH, Kepler CY, Raymond MA, Hersh E, Dorr RT.

Anticancer Drugs. 2006 Nov;17(10):1179-84.

PMID:
17075317
8.

Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.

Moehler TM, Feneberg R, Ho AD, Golenkov AK, Ludwig H, Kropff M, Khuageva NK, Hajda J, von Broen I, Goldschmidt H.

Anticancer Drugs. 2010 Aug;21(7):708-15. doi: 10.1097/CAD.0b013e32833b975b.

PMID:
20571355
9.

Induction of mitochondrial changes in myeloma cells by imexon.

Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT.

Blood. 2001 Jun 1;97(11):3544-51.

10.

Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon.

Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT.

Biochem Pharmacol. 2000 Sep 15;60(6):749-58.

PMID:
10930529
11.

Preclinical pharmacokinetics and antitumor activity of imexon.

Dorr RT, Liddil JD, Klein MK, Hersh EM.

Invest New Drugs. 1995;13(2):113-6.

PMID:
8617572
12.

Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.

Dorr RT, Raymond MA, Landowski TH, Roman NO, Fukushima S.

Int J Gastrointest Cancer. 2005;36(1):15-28.

PMID:
16227632
13.

Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

Scott J, Dorr RT, Samulitis B, Landowski TH.

Cancer Chemother Pharmacol. 2007 May;59(6):749-57.

14.

Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.

Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus RB.

Clin Cancer Res. 2004 Feb 15;10(4):1481-91.

15.

A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma.

Cohen SJ, Zalupski MM, Conkling P, Nugent F, Ma WW, Modiano M, Pascual R, Lee FC, Wong L, Hersh E.

Am J Clin Oncol. 2015 Dec 24. [Epub ahead of print]

PMID:
26709865
16.

Correlates of imexon sensitivity in human multiple myeloma cell lines.

Samulitis BK, Landowski TH, Dorr RT.

Leuk Lymphoma. 2006 Jan;47(1):97-109.

PMID:
16321833
17.

Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.

Cho H, Koto M, Riesterer O, Molkentine DP, Giri U, Milas L, Story MD, Ha CS, Raju U.

Anticancer Res. 2009 Nov;29(11):4409-15.

18.

Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells.

Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT.

Anticancer Drugs. 2002 Nov;13(10):1031-42.

PMID:
12439337
19.

Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy.

Hersh EM, Grogan TM, Funk CY, Taylor CW.

J Immunother Emphasis Tumor Immunol. 1993 Feb;13(2):77-83.

PMID:
8391308
20.

Supplemental Content

Support Center